theory clinical_1_4
imports Main

begin

typedecl entity
typedecl event

consts
  Olaparib :: "entity ⇒ bool"
  Rucaparib :: "entity ⇒ bool"
  PARP1Inhibitor :: "entity ⇒ bool"
  LicensedForUseIn :: "entity ⇒ entity ⇒ bool"
  CancerPatient :: "entity ⇒ bool"
  ProstateCancer :: "entity ⇒ bool"
  PotentialTreatmentOption :: "entity ⇒ entity ⇒ bool"
  Patient :: "entity ⇒ bool"
  LossOfBRCA2 :: "entity ⇒ bool"
  DueToMechanismOfAction :: "entity ⇒ bool"
  PARP1Inhibition :: "entity ⇒ bool"
  SyntheticLethality :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Source :: "event ⇒ entity ⇒ bool"
  DueTo :: "event ⇒ entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Cell :: "entity ⇒ bool"
  Rely :: "event ⇒ bool"
  Mechanism :: "entity ⇒ bool"
  Repair :: "event ⇒ bool"
  DamageToDNA :: "entity ⇒ bool"
  Make :: "event ⇒ bool"
  ViableTreatmentOption :: "entity ⇒ bool"
  TreatmentOption :: "entity ⇒ bool"
  For :: "entity ⇒ entity ⇒ bool"
  Potential :: "entity ⇒ bool"

(* Explanation 1: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a potential treatment option for any patient with loss of BRCA2 due to its mechanism of action. *)
axiomatization where
  explanation_1: "∀x y z. Olaparib x ∧ PARP1Inhibitor x ∧ LicensedForUseIn x y ∧ CancerPatient y ∧ ProstateCancer y ∧ PotentialTreatmentOption x z ∧ Patient z ∧ LossOfBRCA2 z ∧ DueToMechanismOfAction x"

(* Explanation 2: Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a potential treatment option for any patient with loss of BRCA2 due to its mechanism of action. *)
axiomatization where
  explanation_2: "∀x y z. Rucaparib x ∧ PARP1Inhibitor x ∧ LicensedForUseIn x y ∧ CancerPatient y ∧ ProstateCancer y ∧ PotentialTreatmentOption x z ∧ Patient z ∧ LossOfBRCA2 z ∧ DueToMechanismOfAction x"

(* Explanation 3: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality, which causes cells to rely on a singular mechanism to repair cumulative damage to DNA, making Olaparib and Rucaparib viable treatment options. *)
axiomatization where
  explanation_3: "∀x y z e1 e2 e3 a b. Patient x ∧ LossOfBRCA2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Benefit e1 ∧ Agent e1 x ∧ Source e1 y ∧ DueTo e1 z ∧ Cause e2 ∧ Agent e2 z ∧ Cell y ∧ Rely e3 ∧ Agent e3 y ∧ Mechanism z ∧ Repair e3 ∧ DamageToDNA z ∧ Make e3 ∧ Agent e3 z ∧ Olaparib a ∧ ViableTreatmentOption a ∧ Rucaparib b ∧ ViableTreatmentOption b"

theorem hypothesis:
  assumes asm: "Patient y"
  (* Hypothesis: There are two potential treatment options for this patient. *)
  shows "∃x. TreatmentOption x ∧ Patient y ∧ Potential x ∧ For x y"
proof -
  (* From the premise, we have the known information about the patient. *)
  from asm have "Patient y" by simp
  (* Explanation 1 and Explanation 2 provide information about Olaparib and Rucaparib being potential treatment options for patients with loss of BRCA2. *)
  (* Explanation 3 states that patients with loss of BRCA2 may benefit from PARP1 inhibition, making Olaparib and Rucaparib viable treatment options. *)
  (* Using the logical relations, we can infer that both Olaparib and Rucaparib are potential treatment options for the patient. *)
  have "Olaparib x ∧ PotentialTreatmentOption x y ∧ Patient y ∧ LossOfBRCA2 y" by (simp add: explanation_1)
  have "Rucaparib x ∧ PotentialTreatmentOption x y ∧ Patient y ∧ LossOfBRCA2 y" using explanation_2 by blast
  (* Therefore, there are two potential treatment options for this patient. *)
  then show ?thesis sledgehammer
qed

end
